Monday, 25 Mar 2019

You are here

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia.  While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events.  A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.

Xie et al, performed a cohort analysis using  Medicare and MarketScan claims data on RA patients who initiated biologic therapies between 2006 and 2-15, looking for specific CV outcomes including myocardial infarction, stroke, and fatal CVD, 

From 88,463 RA patients they calculated the risk of CV events (crude incidence rate (IR) per 1000 patient‐years to range from 11.8 for etanercept to 17.3 for rituximab users. The crude incidence rate for pooled TNFi users was 15.0 (13.9‐16.3).

When compared to tocilizumab, the adjusted hazard ratios for CV events with biologics were:

  • Abatacept 1.01 (0. 79‐1.28)
  • Rituximab 1.16 (0.89‐1.53)
  • Etanercept 1.10 (0.80‐1.51)
  • Adalimumab 1.33 (0.99‐1.80)
  • Infliximab 1.61 (1.22‐2.12) for infliximab.

The data were similar using Marketscan data showing were no statistically significant differences in CVD risk between tocilizumab and any other biologics

Tocilizumab was associated with CVD risk comparable to etanercept, as well as a number of other RA biologics.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

No Rise in Cancer Risk with Actemra

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

First Line IL-1 Inhibition in Systemic JIA

First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.

Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis

The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study. 

Safety Warnings for Higher Dose Tofacitinib

Pfizer has issued a press release regarding the safety of tofacitinib, citing higher rates of pulmonary embolism and death associated with the use of higher dose tofacitinib 10mg bid in rheumatoid arthritis (RA) patients treated in a long-term safety trial.  

Stopping Biologics Before Joint Surgery: Is Earlier Better?

Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.